Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China

• DOI: 10.1007/s00415-024-12442-w
• Publication Date: 2024-07-02T07:02:33Z
• Authors: Xiaoli Yao; Jing Peng; Rong Luo; Xiuxia Wang; Xinguo Lu; Liwen Wu; Ruifeng Jin; Jianmin Zhong; Jianmin Liang; Siqi Hong; Lin Yang; Xiaoli Zhang; Shanshan Mao; Jun Hu; Zhe Tao; Dan Sun; Hua Wang; Li Zhang; Yanyan Xia; Ken Chen; Yi Wang
• Keywords: Male; China; Original Communication; Adolescent; Oligonucleotides; Infant; Spinal Muscular Atrophies of Childhood; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Child, Preschool; Humans; Female; Registries; Longitudinal Studies; Prospective Studies; Child; Retrospective Studies

Abstract Objective To evaluate the effectiveness and safety of nusinersen for the treatment of 5q-spinal muscular atrophy (SMA) among Chinese pediatric patients.

Methods Using a longitudinal, multi-center registry, both prospective and retrospective data were collected from pediatric patients with 5q-SMA receiving nusinersen treatment across 18 centers in China. All patients fulfilling the eligibility criteria were included consecutively. Motor function outcomes were assessed post-treatment by SMA type. Safety profile was evaluated among patients starting nusinersen treatment post-enrollment. Descriptive analyses were used to report baseline characteristics, effectiveness, and safety results.

Results As of March 2nd, 2023, 385 patients were included. Most patients demonstrated improvements or stability in motor function across all SMA types. Type II patients demonstrated mean changes [95% confidence interval (CI)] of 4.4 (3.4–5.4) and 4.1 (2.8–5.4) in Hammersmith Functional Motor Scale-Expanded (HFMSE), and 2.4 (1.7–3.1) and 2.3 (1.2–3.4) in Revised Upper Limb Module (RULM) scores at months 6 and 10. Type III patients exhibited mean changes (95% CI) of 3.9 (2.5–5.3) and 4.3 (2.6–6.0) in HFMSE, and 2.1 (1.2–3.0) and 1.5 (0.0–3.0) in RULM scores at months 6 and 10. Of the 132 patients, 62.9% experienced adverse events (AEs). Two patients experienced mild AEs (aseptic meningitis and myalgia) considered to be related to nusinersen by the investigator, with no sequelae.

Conclusions These data underscore the significance of nusinersen in Chinese pediatric patients with SMA regarding motor function improvement or stability, and support recommendations on nusinersen treatment by Chinese SMA guidelines and continuous coverage of nusinersen by basic medical insurance.